The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effec ...

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo®) ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ: GILD) ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

There are over 100,000 HIV+ Texans. Trump's 'big beautiful' bill would slash funding for federal HIV prevention, medications, ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.